STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Company Overview

Amgen Inc. is an American multinational biopharmaceutical company that has played a pivotal role in establishing the biotechnology industry since its inception in 1980. Headquartered in Thousand Oaks, California, Amgen has built a reputation for developing and delivering innovative, technology-driven therapeutics designed to address some of the world’s toughest medical challenges. As a company renowned for its expertise in biotechnology-based human therapeutics, Amgen focuses on translational scientific research that turns cutting-edge genetic insights into effective therapies. Key industry terms such as biotherapeutics, monoclonal antibodies and biosimilars are naturally integrated into its core narrative.

Core Business Areas

Amgen operates across multiple therapeutic segments, addressing significant unmet medical needs in areas including:

  • Oncology: With a robust portfolio of cancer therapies, Amgen has developed drugs that target various forms of cancer by leveraging innovative approaches such as targeted inhibition of key cellular pathways.
  • Inflammatory Diseases: The company develops therapies aimed at modulating inflammatory responses, which are critical to treating autoimmune conditions and chronic inflammatory disorders.
  • Bone Health and Metabolic Disorders: Amgen’s products include treatments that support bone strength and manage metabolic dysfunctions, offering solutions for conditions like osteoporosis.
  • Rare Diseases: Through precise research and focused clinical trials, Amgen addresses rare and orphan conditions with innovative treatment options that often involve novel mechanisms of action.

Innovation, Research, and Development

Amgen is widely acknowledged for its investment in research and development (R&D), which is the backbone of its innovative portfolio. The company employs state-of-the-art technologies and leverages human genetic data to develop new therapies. This commitment to innovation is reflected in its constant evolution of therapeutic strategies, from the development of first-in-class drugs to the expansion of biosimilar portfolios. Its achievements are supported by rigorous clinical research, meticulous regulatory compliance and robust post-market surveillance—all of which underscore its expertise in biotechnology.

Scientific and Business Model Excellence

The company’s business model intertwines heavy R&D investment with strategic collaborations and partnerships. Amgen operates not only by developing proprietary molecules but also by engaging in licensing, acquisitions and joint ventures that expand its reach and diversify its portfolio. These initiatives help Amgen sustain a broad pipeline of novel therapies while maintaining quality standards in an intensely competitive and highly regulated industry.

Global Market Position and Collaborations

Amgen occupies a prominent position in the global pharmaceutical landscape. With deep expertise in biologics and a commitment to addressing serious diseases, it is frequently compared to other pharmaceutical giants. Its inclusion in prestigious indices such as the Dow Jones Industrial Average and the Nasdaq-100 reinforces its reputation as a stalwart in the market. The company’s global collaborations, including partnerships with other leading entities in research and pharmaceutical manufacturing, enable it to bring innovative treatments to rigorous markets worldwide.

Commitment to Quality and Patient Outcomes

At the core of Amgen’s mission is a dedication to improving patient outcomes by addressing complex health challenges with scientific rigor. Its strategic approach emphasizes the development of targeted therapies aimed at altering disease trajectories. By focusing on precise mechanisms such as monoclonal antibody technology and the use of genetic insights, Amgen ensures that its products are supported by substantial clinical evidence and scientific validation. This commitment not only enhances its credibility among medical professionals but also reinforces trust among patients and regulatory bodies.

Operational Excellence and Market Adaptability

Amgen’s operational framework is built upon robust manufacturing capabilities and an efficient supply chain that meet global standards. The company’s investments in technology and continuous process improvements underscore its adaptability in a dynamic market. Its focus on both innovation and quality control has enabled it to sustain long-term growth and mitigate risks associated with product development and market competition. As a result, Amgen consistently demonstrates both operational resilience and an unwavering commitment to scientific excellence.

Conclusion

In summary, Amgen Inc. represents a quintessential blend of innovation, scientific prowess, and operational excellence. By integrating advanced genetic research with a diverse therapeutic portfolio, the company continually pushes the boundaries of what is possible in human therapeutics. Its structured business model, underpinned by extensive clinical research and strategic global collaborations, ensures that Amgen remains at the forefront of the biotechnology arena. This comprehensive approach not only cements its position in the competitive pharmaceutical landscape but also delivers enduring value to patients and the broader healthcare community.

Rhea-AI Summary

Amgen (NASDAQ: AMGN) has partnered with actress and entrepreneur La La Anthony to share her personal journey with plaque psoriasis and encourage open dialogue between patients and doctors about the disease's impact on daily life. La La, one of over 6 million Americans with plaque psoriasis, offers an intimate look at how the condition affects her personal and professional life in a new interactive video.

The campaign aims to raise awareness about the challenges of managing plaque psoriasis and the importance of finding suitable treatment options. La La emphasizes the need for patients to be vocal about how treatments impact their lifestyle. The initiative also highlights that plaque psoriasis is an autoimmune disease starting with internal inflammation, not just a skin condition.

Amgen's partnership with La La Anthony supports their commitment to helping plaque psoriasis patients access affordable treatment options, including Otezla® (apremilast), an oral medication that addresses underlying inflammation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
partnership
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) announced that TEPEZZA® (teprotumumab) has been approved in Japan for the treatment of active Thyroid Eye Disease (TED) by Japan's Ministry of Health, Labour and Welfare. TED is a serious, progressive autoimmune disease affecting approximately 25,000 - 35,000 people in Japan. TEPEZZA is the first and only medicine approved in Japan to treat active TED.

The approval was based on the positive results of the OPTIC-J Phase 3 study, where 89% of patients treated with TEPEZZA showed clinically meaningful improvement in proptosis compared to 11% with placebo. TEPEZZA received orphan drug designation in Japan, allowing for a faster regulatory review. A separate trial for chronic TED patients in Japan is ongoing.

This marks TEPEZZA's first approval in Asia, offering a nonsurgical and nonsteroidal option that treats a root cause of TED. TEPEZZA is also approved in the United States, Brazil, and Saudi Arabia, and is under review in Europe, Canada, and Australia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.46%
Tags
none
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) has announced a webcasted conference call for the investment community on Tuesday, September 24, 2024, at 1:30 p.m. PT. The call will focus on discussing new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA® (inebilizumab-cdon) Phase 3 programs.

Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, along with other team members, will participate in the call. The webcast will be accessible to news media, investors, and the general public via Amgen's website at www.amgen.com under the Investors section.

The webcast will be archived and available for replay for at least 90 days after the event. Information about presentation times, webcast availability, and links can be found on Amgen's Investor Relations Events Calendar.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences
Rhea-AI Summary

Amgen (NASDAQ: AMGN) announced new data presentations at the European Society for Medical Oncology (ESMO) Congress 2024, showcasing its oncology pipeline and portfolio. Key presentations include:

1. Phase 1b study results of LUMAKRAS® plus Vectibix® with FOLFIRI for first-line KRAS G12C-mutated metastatic colorectal cancer.

2. Phase 1 data on AMG 193, an MTA-cooperative PRMT5 inhibitor, selected for a presidential symposium.

3. First-in-human study of xaluritamig for metastatic castration-resistant prostate cancer.

The presentations cover various cancer types, including colorectal, lung, prostate, and gastric cancers, using molecularly targeted therapies. This diverse data set reflects Amgen's strategy to advance multiple modalities for difficult-to-treat cancers, showcasing their leadership in oncology research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences clinical trial
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) presented new data for IMDELLTRA™ (tarlatamab-dlle), a first-in-class DLL3-targeting BiTE® molecule, at the 2024 World Conference on Lung Cancer. The DeLLphi-303 study showed promising results for IMDELLTRA in combination with PD-L1 inhibitors as first-line maintenance therapy in ES-SCLC. Key findings include:

- Disease control rate of 62.5% for both IMDELLTRA plus durvalumab and atezolizumab
- 9-month overall survival of 91.8% with durvalumab and 86.7% with atezolizumab
- Manageable safety profile with no new safety concerns

Extended follow-up data from the DeLLphi-301 Phase 2 study demonstrated sustained anticancer activity in previously treated ES-SCLC patients, with a 40% objective response rate and median overall survival of 15.2 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) has announced its participation in the 2024 Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024 at 9:30 a.m. ET. Peter Griffith, executive vice president and CFO, and Jay Bradner, executive vice president of Research and Development and CSO, will represent Amgen at the event.

The presentation will be webcast live and made available to the public, media, and investors. The webcast can be accessed on Amgen's website (www.amgen.com) under the Investors section. Amgen's Investor Relations Events Calendar provides details on presentation times and webcast links. The webcast will be archived for at least 90 days after the event for later viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
conferences
Rhea-AI Summary

Amgen (NASDAQ:AMGN) is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4, 2024, at 9:15 a.m. ET. Robert A. Bradway, Amgen's chairman and CEO, will be presenting at the event.

The presentation will be webcast live and made available to the public, media, and investors. Interested parties can access the webcast through Amgen's website (www.amgen.com) under the Investors section. The company's Investor Relations Events Calendar provides details on presentation times and webcast links.

This webcast, along with other selected presentations on Amgen's business developments, will be archived and available for replay for at least 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) announced that Otezla® (apremilast) is now available in the U.S. for pediatric use, following FDA approval for treating moderate to severe plaque psoriasis in children and adolescents ages 6 and older weighing at least 20 kg. This marks the first and only FDA-approved oral medication for this condition in this patient population.

The approval was based on the SPROUT Phase 3 study, which demonstrated significant efficacy with a 33.1% sPGA response for Otezla versus 10.8% for placebo. The safety profile was consistent with that observed in adult patients. Dosage is weight-based, with 20 mg or 30 mg administered twice daily after initial titration.

This expansion of Otezla's use represents a new treatment option for younger patients with plaque psoriasis, potentially offering relief to many who previously had choices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
Rhea-AI Summary

Amgen (NASDAQ: AMGN) reported its Q2 2024 financial results showing a 20% revenue increase to $8.4 billion compared to Q2 2023. Product sales grew by 20% with a 26% volume boost, albeit offset by a 3% decline in net selling price. Excluding Horizon Therapeutics' sales, product sales were up by 5%.

GAAP EPS fell 46% to $1.38, affected by higher operating costs, while non-GAAP EPS decreased 1% to $4.97. Free cash flow dropped to $2.2 billion from $3.8 billion due to timing of tax payments. The company remains on track to reduce its debt by more than $10 billion by the end of 2025.

Strong performers included Prolia® (13% sales increase), Repatha® (25%), and TEZSPIRE® (76%). However, some products like Enbrel® and Otezla® saw declines in sales. Amgen's guidance for 2024 predicts revenue between $32.8 billion and $33.8 billion, with GAAP EPS between $6.57 and $7.62, and non-GAAP EPS between $19.10 and $20.10.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
Rhea-AI Summary

Amgen (NASDAQ:AMGN) has announced its third quarter dividend for 2024. The company's Board of Directors has declared a dividend of $2.25 per share, which will be paid on September 6, 2024. This dividend is available to all stockholders of record as of the close of business on August 16, 2024. This announcement demonstrates Amgen's commitment to providing regular returns to its shareholders, which may be viewed positively by investors looking for stable income-generating stocks in the biotechnology sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
dividends

FAQ

What is the current stock price of Amgen (AMGN)?

The current stock price of Amgen (AMGN) is $294.39 as of April 4, 2025.

What is the market cap of Amgen (AMGN)?

The market cap of Amgen (AMGN) is approximately 164.9B.

What is the core business of Amgen Inc.?

Amgen is a biopharmaceutical company focused on developing innovative therapeutics, primarily in oncology, inflammation, bone health, and rare diseases.

How does Amgen generate revenue?

Amgen generates revenue through extensive research and development, proprietary drug manufacturing, licensing, strategic acquisitions, and global-commercial partnerships.

What therapeutic areas does Amgen focus on?

The company targets multiple therapeutic areas including cancer therapy, inflammatory and autoimmune conditions, bone health, metabolic disorders, and rare diseases.

How does Amgen demonstrate its commitment to innovation?

Amgen invests heavily in R&D, leveraging advanced genetic data and state-of-the-art biotechnology to develop first-in-class drugs and expand its biosimilar portfolio.

What role do partnerships play in Amgen's business model?

Partnerships are crucial for Amgen; they engage in strategic collaborations, joint ventures, and licensing agreements to broaden their therapeutic pipelines and market reach.

How is Amgen positioned in the global market?

Amgen is a market heavyweight, recognized in prestigious indices like the Dow Jones Industrial Average and Nasdaq-100 for its innovation, operational excellence, and global presence.

What distinguishes Amgen from its competitors?

Its deep expertise in biotechnology, substantial R&D investments, strong clinical evidence, and strategic global collaborations set Amgen apart in the competitive pharmaceutical industry.

How does Amgen maintain product quality and regulatory compliance?

Through rigorous research, validated clinical trials, robust manufacturing processes, and strict adherence to global regulatory standards, Amgen consistently ensures high-quality and safe therapies.
Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

164.90B
536.02M
0.22%
82.06%
3.01%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
THOUSAND OAKS